• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

inclisiran

heart
Posted inCardiology, Clinical Trials, In the Pipeline, Metabolism

Enlicitide: Very Strong Pill Against ‘Bad’ Cholesterol

by Julia Mardi February 27, 2024April 19, 2024

The oral drug by Merck & Co. smashes all competitors for the treatment and prevention of atherosclerosis.

Posted inCardiology, Metabolism, New Drugs, Rare/Orphan Diseases, Regulatory

Leqvio: Newest Drug Against ‘Very Bad’ Cholesterol

by Mark Gubar December 23, 2021April 5, 2024

Two injections of inclisiran a year and you can forget about high cholesterol. Novartis doesn’t lie.

BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×